ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug (IND)-enabling ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Structure Therapeutics Inc. - Depositary ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) today and ...

Citizens JMP lowered the firm’s price target on Structure Therapeutics (GPCR) to $87 from $91 and keeps an Outperform rating on the shares.

OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel ...

William Blair started coverage on shares of Structure Therapeutics (NASDAQ:GPCR – Free Report) in a research note published on Friday, Marketbeat Ratings reports. The brokerage issued an outperform ...

Innoviva's shift to specialty therapeutics is backed by strong financials and a robust pipeline. Read why INVA stock presents ...

Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.

The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?